Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
NCT07726147Phase 1Recruiting
- Sponsor
- Immunomic Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ITI-9001 in Japanese cedar pollinosis[1][3] (3 arms), sponsored by Immunomic Therapeutics, Inc. Primary endpoint: Dose-limiting toxicities at Day 382. Started Jun 2026; status: recruiting.
02
Drugs
ITI-9001
03
Conditions
Japanese cedar pollinosis[1][3]
Beyond the preview
Go deeper on NCT07726147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726147.